Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy
暂无分享,去创建一个
S. Löck | M. Krause | T. Lange | S. Perner | H. Neubauer | F. Lohaus | A. Linge | A. Dubrovska | C. Peitzsch | Monica Cojoc | I. Kurth | P. Dowling | M. Kücken | T. Hölscher | B. Polzer | M. Baumann | A. Offermann | A. Franken | M. Rivandi | D. Husman | D. Klusa | Vera Freytag | Marian Baumbach
[1] S. Löck,et al. Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P) , 2022, Cancers.
[2] P. Sarret,et al. The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers , 2021, Cancer and Metastasis Reviews.
[3] M. Krause,et al. The distinct role of ALDH1A1 and ALDH1A3 in the regulation of prostate cancer metastases , 2021, bioRxiv.
[4] M. Krause,et al. Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response , 2021, Frontiers in Oncology.
[5] Jin-hai Tang,et al. Heterogeneity of CTC contributes to the organotropism of breast cancer. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[6] V. Khoo,et al. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials. , 2020, European urology oncology.
[7] C. Lefebvre,et al. An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer. , 2020, European urology oncology.
[8] Ash A. Alizadeh,et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer , 2020, JAMA oncology.
[9] N. Morrison,et al. Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) Drives Activation of Bone Remodelling and Skeletal Metastasis , 2019, Current Osteoporosis Reports.
[10] M. Jolly,et al. Phenotypic heterogeneity in circulating tumor cells and its prognostic value in metastasis and overall survival , 2019, EBioMedicine.
[11] N. Lawrentschuk,et al. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. , 2018, European urology.
[12] N. Stoecklein,et al. Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis , 2018, Clinical Cancer Research.
[13] D. Lorente,et al. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] M. Cooperberg,et al. Identification and characterization of circulating tumor cells in post prostatectomy patients with localized high risk prostate cancer. , 2018 .
[15] D. Haber,et al. A conduit to metastasis: circulating tumor cell biology , 2017, Genes & development.
[16] Amy R. Peck,et al. Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth , 2017, Oncotarget.
[17] T. Schlomm,et al. Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients , 2016, Scientific Reports.
[18] E. Heath,et al. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis , 2016, Molecular Cancer.
[19] H. Scher,et al. Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer , 2016, European urology.
[20] K. Tabata,et al. Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer , 2016, International journal of molecular sciences.
[21] E. Schröck,et al. An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells. , 2016, Cancer research.
[22] James E. Verdone,et al. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters , 2016, Proceedings of the National Academy of Sciences.
[23] P. Nilsson,et al. Very low rate of circulating tumour cells (CTCs) in patients with PSA recurrence after radical prostatectomy referred to salvage radiotherapy , 2016, Acta oncologica.
[24] M. Lock,et al. The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy , 2015, Prostate Cancer and Prostatic Disease.
[25] Hosung Jung,et al. Localized CCR2 Activation in the Bone Marrow Niche Mobilizes Monocytes by Desensitizing CXCR4 , 2015, PloS one.
[26] M. Wirth,et al. Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. , 2015, Cancer research.
[27] Sridhar Ramaswamy,et al. Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis , 2014, Cell.
[28] S. Rosati,et al. CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model , 2014, Clinical & Experimental Metastasis.
[29] A. Dubrovska,et al. CXCR4 as biomarker for radioresistant cancer stem cells , 2014, International journal of radiation biology.
[30] A. Voigt,et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. , 2014, Cancer research.
[31] Tim Holland-Letz,et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay , 2013, Nature Biotechnology.
[32] B. Kong,et al. Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-β1 , 2013, Cellular and Molecular Immunology.
[33] P. Schultz,et al. CXCR4 Expression in Prostate Cancer Progenitor Cells , 2012, PloS one.
[34] Oscar Lin,et al. Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer , 2009, Clinical Cancer Research.
[35] Glenn Heller,et al. Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.
[36] Richard K Valicenti,et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] M. Rogers,et al. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells , 2007, Molecular Cancer.
[38] E. Messing,et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. , 2006, JAMA.
[39] K. Pienta,et al. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. , 2006, Neoplasia.
[40] T. Fehm,et al. Isolation and characterization of circulating tumor cells using a novel workflow combining the CellSearch® system and the CellCelector™ , 2017, Biotechnology progress.
[41] R. Matkowski,et al. Circulating Tumor , 2014 .